Gout disease-specific quality of life and the association with gout characteristics

Jan D Hirsch, Robert Terkeltaub, Dinesh Khanna, Jasvinder Singh, Andrew Sarkin, Micki Shieh, Arthur Kavanaugh, Susan J Lee, Jan D Hirsch, Robert Terkeltaub, Dinesh Khanna, Jasvinder Singh, Andrew Sarkin, Micki Shieh, Arthur Kavanaugh, Susan J Lee

Abstract

PURPOSE: Assess the association of gout characteristics with health-related quality of life (HRQoL) using a new gout-specific HRQoL instrument, the Gout Impact Scale (GIS). PATIENTS AND METHODS: Gout patients completed the GIS (five scales [0-100 score each] representing impact of gout overall [three scales] and during an attack [two scales]) and other questions describing recent gout attacks, treatment, gout history, comorbidities, and demographics. Physicians confirmed gout diagnosis, presence of tophi, and most recent serum uric acid (sUA) level. Relationships between gout characteristics and GIS scores were examined using analysis of variance and correlation analyses. RESULTS: The majority of patients were male (90.2%) with a mean age of 62.2 (±11.8) years. Approximately one-half (49.7%) reported ≥3 gout attacks in the past year and the majority (57.9%) reported experiencing gout-related pain between attacks. Patients had appreciable concern about their gout ("gout concern overall" scale, 63.1 ± 28.0) but believed their treatment was adequate ("unmet gout treatment need" scale (38.2 ± 21.4) below scale mid-point). Significantly worse GIS scores were associated with increasing attack frequency and greater amount of time with pain between attacks (most scales, P < 0.001). Common objective measures such as sUA level, presence of tophi and the number of joints involved in a typical attack did not appear to be good indicators of the impact of gout on the patients' HRQoL. CONCLUSION: Attack frequency and gout pain between attacks were important correlates of patients' ratings of gout impact on their HRQoL. Further studies are needed to determine the minimal important difference for each GIS scale and interpret our results relative to other patient populations with gout.

References

    1. Kim KY, Schumacher HR, Hunsche E, et al. A literature review of the epidemiology and treatment of acute gout. Clin Ther. 2003;25:1593–1617.
    1. Adams PF, Hendershot GE, Marano MA. Centers for Disease Control and Prevention/National Center for Health Statistics. Current estimates from the National Health Interview Survey, 1996. Vital Health Stat. 1999;10(200):1–203.
    1. Osterhaus JT, Patel P, Palo W, et al. Patient reported outcomes associated with gout: Baseline results from two clinical trials. San Diego, CA. Presented at the Annual Meeting of the American College of Rheumatology; 2005.
    1. Alvarez-Nemegyei J, Cen-Pisté JC, Medina-Escobedo M, et al. Factors associated with musculoskeletal disability and chronic renal failure in clinically diagnosed primary gout. J Rheumatol. 2005;32:1923–1927.
    1. Vázquez-Mellado J, Cruz J, Guzman S, et al. Severe tophaceous gout. Characterization of low socioeconomic level patients from Mexico. Clinl Exp Rheumatol. 2006;24(3):233–238.
    1. Geletka RC, Hershfield MS, Scarlett THE, et al. Severe gout is associated with impaired quality of life and functional status [abstract] Arthritis Rheum. 2004;50((9)(suppl)):S340–S341.
    1. Khanna D, Mansoor A, Yontz D, et al. The disutility of chronic gout. Qual Life Res. 2008;17(5):815–822.
    1. Khanna D, Mansoor A, Yontz D, et al. Willingness to pay for a cure in patients with chronic gout. Med Decis Making. 2008;28(4):606–613.
    1. National Institute for Health and Clinical Excellence Febuxostat for the management of hyperuricaemia in people with gout. Available from: . Accessed January 12, 2009.
    1. Taylor WJ, Schumacher HR, Singh JA, et al. Assessment of outcome in clinical trials of gout – a review of current measures. Rheumatology. 2007;46(12):1751–1756.
    1. Taylor WJ, Schumacher HR, Jr, Baraf HS, et al. A modified Delphi exercise to determine the extent of consensus with OMERACT outcome domains for studies of acute and chronic Gout. Ann Rheum Dis. 2008;67:888–891.
    1. Sundy JD, Schumacher HR, Becker MA, et al. Quality of life in patients with treatment failure gout. Ann Rheum Dis. 2006;65(Suppl II):271.
    1. Geletka RC, Hershfield MS, Scarlett EL, et al. Severe gout is associated with impaired quality of life and functional status. Arthritis Rheum. 2004;50:S340–S341.
    1. Lee SJ, Hirsch JD, Terkeltaub R, et al. Perceptions of disease and health-related quality of life among patients with gout. Rheumatology. 2009;48(5):582–586.
    1. Picavet HJ, Hoetmans N. Health related quality of life in multiple muscoloskelatal diseases: Sf-36 and EQ-5D in the DMC3 study. Ann Rheum Dis. 2004;63:723–729.
    1. Roddy E, Zhang W, Doherty M. Is gout associated with reduced quality of life? A case-control study. Rheumatology. 2007;46:1441–1444.
    1. Singh J, Strand V. Gout is associated with more comorbidities, poorer health related quality of life and higher health care utilization in US veterans. Ann Rheum Dis. 2008;67(9):1310–1316.
    1. Bootman JL, Townsend RJ, McGhan WF, editors. Principles of pharmacoeconomics. 3rd edition. Cincinnati, OH: Harvey Whitney Books Company; 2005. p. 157.
    1. Hirsch JD, Lee SJ, Terkeltaub R, et al. Evaluation of an instrument assessing gout association on health-related quality of life. J Rheumatol. 2008;35(12):2406–2414.
    1. Cohen J, Cohen P, West SG, et al. Applied Multiple Regression/ Correlation Analysis for the Behavioral Sciences. 2nd edition. Hillsdale, NJ: Lawrence Erlbaum Associates; 2003.

Source: PubMed

3
구독하다